How your donations are making an impact:
Our 2016 Funds: All profits go toward funding brain tumor awareness, research, and the neurological consequences of their removal as well as honoring bravery in everyday heroes. The recipients of our 2016 fundraising efforts are: Barrow Neurological Institute, Boston Children’s Hospital, Dr. Edward Smith and Bill Muench.
Barrow Neurological Institute:
In early February 2017, Dr. Joseph Zabramski’s team at Barrow Neurological Institute was the recipient of a $75,000 grant from the Be Brave for Life Foundation in support of their continued research into a new treatment for vascular brain tumors, or CCMs (Cerebral Cavernous Malformations). They recently completed necessary preparation and design for a clinical research protocol at Barrow that promises to provide insight into the mechanism of propranolol’s effect on CCMs. Patients who are scheduled for surgical resection for symptomatic brain stem CCMs will be offered enrollment in a clinical protocol. If the patient chooses to participate he/she will be divided into one of two groups; the treatment group will receive propranolol 20mg orally three times per day, and the control group will receive placebo three times per day. Samples of the surgically resected CCMs from these two groups will be collected and will be subjected to global messenger RNA and micro RNA (see Appendix B) expression profiling to identify regulatory networks involved in effects produced by propranolol therapy for CCMs. The initial goal will be to enroll 20 patients (10 in the treatment group and 10 in the placebo group). The research team expects to complete enrollment by summer of 2017. Knowledge regarding the potential mechanisms of propranolol’s effect on CCMs is essential to obtaining government funding for a Phase III clinical trial.
Be Brave for Life’s financial support will provide for the administrative and medical staff required—including but not limited to a clinical nurse research coordinator—to accurately collect and monitor results of the proposed research protocol. The costs of genomic studies will also be offset with the support from Be Brave for Life. Our support will enable Dr. Zabramski and his team to take this important step in discovering new treatment options for people living with CCMs.
Boston Children’s Hospital:
Dr. Edward Smith:
In October 2016, Be Brave for Life honored Dr. Smith with a $1,000 grant for his bravery for working tirelessly to search for a cure for vascular disease and brain tumors, especially in pediatrics. https://bebrave.life/spotlight-nominee-dr-edward-smith/
In October 2016, Be Brave for Life honored Bill with a $1,000 grant for his bravery in starting a cinematography program at Burr and Burton Academy after his good friend and colleague Brian Gawlik passed away. https://bebrave.life/spotlight-nominee-bill-muench/
Where the money went last year:
Our 2015 Funds:
Barrow Neurological Clinical Trial: In March 2016, Be Brave donated $40,000 to Dr. Joseph Zabramski’s lab at Barrow Neurological Institute, BNI, in Phoenix, Arizona. Dr. Zabramski is one of BNI’s leading neurosurgeons and researchers. He and his team are conducting a Phase II clinical trial to establish the feasibility and safety of using an oral medication, propranolol, as an alternative approach to the treatment of vascular brain tumors, or CCMs (Cerebral Cavernous Malformations), in adults and children. If the trial hypothesis is confirmed, this study will pave the way for a Phase III trial – one step closer to delivering this medication to patients with CCMs, people like Riley.
The advancements of 2016
It has been an exciting year for Dr. Zabramski and his research partners, Barrow’s Robert Spetzler, MD, Translational Genomics Research Institute’s Matthew Huentelman, PhD, and University of Utah’s Yashar Kalani MD, PhD. A number of clinical trials have demonstrated that propranolol (a low-cost and FDA-approved medication with a long history of widespread clinical use) can significantly shrink cutaneous hemangiomas in infants, and that the drug is extremely safe in this population. Because of the similarities between cutaneous hemangiomas and CCMs we proposed that propranolol may be an ideal candidate for treating both types of lesions.
Based on initial positive research results using oral propranolol published in the April 2016 issue of World Neurosurgery, and with financial support of Be Brave For Life, Dr. Zabramski and his team have continued investigating the use of oral propranolol in a small number of patients at Barrow who are unwilling or unable to consider surgical intervention. Recently, the team presented a proposal for a Phase III clinical trial of oral propranolol at the 12th Annual Scientific Meeting of the Angioma Alliance on November 10th, 2016 in Washington, D.C. The presentation entitled, “A Proposed Trial of Oral Propranolol for Symptomatic Cerebral Cavernous Malformations not Amenable to Surgical Resection,” was well received and there is international interest in this clinical trial. Following the meeting, Drs. Zabramski and Kalani met with the program director of the National Institute of Neurological Disorders and Stroke and National Institutes of Health, Jim Koenig PhD, to discuss government funding for this study. The team is also working with several groups in Italy to submit a joint funding request to the National Institutes of Health later this year.
Boston Children’s Hospital National Trial: Also in March 2016, Be Brave For Life donated $40,000 to Dr. Edward Smith at Boston Children’s Hospital. Dr. Smith’s lab focuses primarily on pediatric brain tumors and vascular disease. He is particularly interested in detecting brain tumors early, as well as why some brain tumors are benign and why others are invasive. Through his efforts they have developed a non-invasive urine test to try to detect tumors earlier and are now testing it in a national trial. With Be Brave For Life’s donation he has begun to expand this work to benign brain tumors so that they can be detected earlier and treated more effectively, while saving healthcare dollars.